Navigation Links
Allergic-like reactions to iodinated contrast material treated safely with commonly used medications

Patients who have had acute allergic-like reactions to nonionic iodinated contrast material rarely develop any serious long-term problems and can be treated safely with commonly used medications according to a recent study conducted by researchers at the University of Michigan Hospitals in Ann Arbor.

"While adverse reactions to iodinated contrast media are rare, they are encountered regularly by all physicians who administer contrast material to patients and some of these reactions will require treatment," said Richard Cohan, MD, lead author of the study. "We reviewed our experience to determine how often we encountered these reactions in our practice and how often the reactions required treatment. We also wanted to know what happened to those patients who required treatment, particularly when they had reactions that were moderate or severe," said Dr. Cohan.

The study consisted of 84,928 IV injections of nonionic iodinated contrast media in adults. In this group, there were 545 (0.6%) patients who had allergic-like reactions, with 221 receiving treatment. The most commonly administered medications were diphenhydramine to 145 (27%) reacting patients, corticosteroids to 17 patients, albuterol to 16 patients, ephinephine to 15 patients, and nitroglycerin to eight patients. According to the study, 99% of the allergic-like reactions resolved completely within 24 hours. This included all 418 patients who had mild reactions, all 116 patients who had moderate reactions, and nine of the 11 patients who had severe reactions.

"Commonly used medications can be administered safely; however, treatment errors are not uncommon and in a few instances can lead to patient morbidity," said Dr. Cohan. "In our study, we found a number of instances in which non-recommended treatment was provided. These cases included the administration of oxygen by nasal cannula (rather than mask) and at lower than recommended doses, over-utilization of diphenhydramine (including to a few patients who were hypotensive), and the administration of higher than recommended doses of epinephrine, as well as occasional confusion about which concentrations of epinephrine should be injected in which manner (subcutaneously or intravenously). In our study, the most striking example of patient morbidity from non-recommended treatment occurred in the two patients who received doses of 1 mg of epinephrine in the absence of cardiopulmonary arrest, who both had cardiac complications. Fortunately, these complications were mild and transient and caused no serious morbidity," he said.

"We hope that after reading our study, radiologists, nurses, and technologists will agree that they must review the algorithms for treating contrast reactions on a regular basis (particularly issues related to diphenhydramine, oxygen, and epinephrine administration)," said Dr. Cohan. "In fact, we would suggest that such a review should probably occur at least twice a year. However, it is also consoling to know that even when patients have moderate or severe contrast reactions, the vast majority recover promptly and without any long term complications," he said.


Contact: Necoya Tyson
American Roentgen Ray Society

Related medicine news :

1. Allergic-like reactions occur in premedicated patients
2. London School of Hygiene to play key role in global collaboration on adverse drug reactions
3. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
4. MDs reactions to pharma marketing influenced by brand, side effects: Management Insights
5. Allergic reactions to gadolinium-based contrast agents are rare, study finds
6. U of I scientists aim to overcome allergic reactions to soy
7. PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements
8. Consumer Alert: Black Henna Tattoos Can Cause Serious Skin Reactions
9. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
10. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
11. DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRis Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
Breaking Medicine Technology: